Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 10:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 45 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Endothelial cell collection Clear all
Completed Phase 2 Interventional Results available

Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme

NCT00621686
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
bevacizumab, sorafenib tosylate
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
204
States / cities
Scottsdale, Arizona • Fresno, California • Fort Collins, Colorado + 129 more
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Sep 3, 2026, 10:33 AM EDT
Not yet recruiting Phase 3 Interventional

Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial

NCT07271355
View directory record Official record
Conditions
Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum, Stage IV Appendix Carcinoma AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
Interventions
Bevacizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Magnetic Resonance Imaging, Mitomycin, Questionnaire Administration
Biological · Procedure · Drug + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
5
States / cities
Goodyear, Arizona • Duarte, California • Irvine, California + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 3, 2026, 10:33 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Role of Endothelial Function in SCI CVD Risk

NCT06443151
View directory record Official record
Conditions
Spinal Cord Injuries, Cardiovascular Diseases, Endothelial Dysfunction
Interventions
Brachial intra-arterial infusion of vasoactive and antioxidant drugs (acetylcholine, nitroprusside, ascorbic acid), venous occlusion plethysmography, Acetylcholine, Sodium Nitroprusside, Ascorbic acid, venous phlebotomy
Procedure · Drug
Lead sponsor
Craig Hospital
Other
Eligibility
18 Years to 89 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Sep 3, 2026, 10:33 AM EDT
Recruiting Phase 1 Interventional

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

NCT06696768
View directory record Official record
Conditions
Metastatic Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Adenocarcinoma
Interventions
Bevacizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Emavusertib, Fluorouracil, Leucovorin Calcium, Magnetic Resonance Imaging, Oxaliplatin, Positron Emission Tomography
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
13
States / cities
Gainesville, Florida • Shiloh, Illinois • Fairway, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 3, 2026, 10:33 AM EDT
Completed No phase listed Observational

Quantitation of Endothelial Progenitor Cells as Markers of Tumor Angiogenesis in Breast Cancer

NCT00393341
View directory record Official record
Conditions
Breast Cancer Stage IV, Breast Cancer Stage I, Breast Cancer Stage II
Interventions
Blood Draw
Procedure
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older · Female only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 30, 2015 · Synced Sep 3, 2026, 10:33 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Endothelial Dysfunction After SCI

NCT07227727
View directory record Official record
Conditions
Spinal Cord Injuries, Endothelial Dysfunction
Interventions
Intra-arterial Infusion of Vasoactive Agents, Intra-arterial Vitamin C Infusion, Blood Sampling
Procedure
Lead sponsor
Craig Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 3, 2026, 10:33 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Investigation of the Effects of Electronic Cigarettes on Vascular Health

NCT03041493
View directory record Official record
Conditions
Vascular Health
Interventions
Electronic cigarette, traditional cigarette, (sham cigarette) - no actual exposure to cigarettes
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Sep 3, 2026, 10:33 AM EDT
Completed Phase 1 Interventional

Endothelial Cell Dysfunction in Pulmonary Hypertension

NCT00098072
View directory record Official record
Conditions
Secondary Pulmonary Arterial Hypertension
Interventions
Heart Catheterization
Procedure
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 100 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 3, 2026, 10:33 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Role of the Space Environment on Vascular Endothelial and Smooth Muscle Cell Processes

NCT03156257
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Blood volume collected specifically for this study
Biological
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 50 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 3, 2026, 10:33 AM EDT
Recruiting No phase listed Observational

Testosterone Deficiency and Endothelial Dysfunction After Spinal Cord Injury

NCT07227740
View directory record Official record
Conditions
Spinal Cord Injuries, Endothelial Dysfunction, Testosterone Deficiency
Interventions
Intra-arterial Infusion of Vasoactive Agents, Intra-arterial Vitamin C Infusion, Blood Sampling
Diagnostic Test
Lead sponsor
Craig Hospital
Other
Eligibility
18 Years to 89 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 3, 2026, 10:33 AM EDT
Recruiting Phase 2 Interventional

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

NCT07288034
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Adagrasib, Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody, Bevacizumab, Biopsy Procedure, Biospecimen Collection, Chemotherapy, Computed Tomography, Durvalumab, Magnetic Resonance Imaging, Monitoring, Positron Emission Tomography, Surveillance, Tremelimumab
Drug · Biological · Procedure + 2 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
13
States / cities
Goodyear, Arizona • Corona, California • Duarte, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 3, 2026, 10:33 AM EDT
Withdrawn Phase 2 Interventional

Effects of Nitric Oxide on the Endothelium During Hemolysis.

NCT03748082
View directory record Official record
Conditions
Endothelial Dysfunction, Hemolysis Intravascular, Cardiovascular Diseases, Cardiovascular Risk Factor
Interventions
Nitric Oxide, Reactive Hyperemia Index, Endothelial Cells Collection
Drug · Diagnostic Test · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Sep 3, 2026, 10:33 AM EDT
Completed Phase 2 Interventional Results available

Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer

NCT00089609
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Docetaxel, Thalidomide, Prednisone, bevacizumab, polymorphism analysis, immunoenzyme technique, laboratory biomarker analysis, pharmacological study
Drug · Biological · Genetic + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 19, 2018 · Synced Sep 3, 2026, 10:33 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Mechanisms of Pregnancy Vascular Adaptations

NCT03806283
View directory record Official record
Conditions
Pre-Eclampsia, Vascular Diseases
Interventions
Omental Biopsy
Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
166 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Sep 3, 2026, 10:33 AM EDT
Completed Phase 1 Interventional Results available

Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors

NCT03250832
View directory record Official record
Conditions
Neoplasms
Interventions
TSR-033, Dostarlimab, mFOLFOX6, FOLFIRI, Bevacizumab
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
11
States / cities
Los Angeles, California • Whittier, California • Sarasota, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Sep 3, 2026, 10:33 AM EDT
Not yet recruiting No phase listed Observational

Vascular Endothelial Inflammation and Health Status In INOCA (VISION-INOCA)

NCT07586241
View directory record Official record
Conditions
Ischemia and Non-obstructive Coronary Arteries
Interventions
Invasive coronary angiography, Coronary Artery Endothelial Cell Sampling, Fitbit, Invasive coronary function testing
Procedure · Device · Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 3, 2026, 10:33 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Blood Collection for Research Related to Certain Diseases Involving Blood Vessels

NCT00047996
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2002
U.S. locations
2
States / cities
Bethesda, Maryland • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 3, 2026, 10:33 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Molecular and Morphologic Characterization of Circulating Endothelial Cells

NCT01005485
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
Not listed
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
664 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Sep 3, 2026, 10:33 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

NCT02971501
View directory record Official record
Conditions
Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8
Interventions
Bevacizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Osimertinib
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
18
States / cities
Los Angeles, California • Pasadena, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 3, 2026, 10:33 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

PAI-1, tPA, TFPI and HEECs in Uterine Hemostasis

NCT05862805
View directory record Official record
Conditions
Menstrual Bleeding, Heavy
Interventions
Sample Collection and Endometrial Biopsy
Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Sep 3, 2026, 10:33 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Nebivolol on Skeletal Muscle During Exercise in Hypertensive Patients

NCT01501929
View directory record Official record
Conditions
Hypertension
Interventions
Metoprolol succinate, Nebivolol, Non-invasive measurement of Cardiac Output (CO), Endothelial cell collection, Microvascular perfusion assessment using Definity
Drug · Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Sep 3, 2026, 10:33 AM EDT
Recruiting Phase 3 Interventional

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

NCT04181060
View directory record Official record
Conditions
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Bevacizumab, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Osimertinib
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
603
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 425 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 3, 2026, 10:33 AM EDT
Terminated No phase listed Observational Results available

Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease

NCT03709771
View directory record Official record
Conditions
Renal Cell Carcinoma, Hypertension, Melanoma, Cancer
Interventions
Ambulatory Blood Pressure Measurement
Diagnostic Test
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
40 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Sep 3, 2026, 10:33 AM EDT